| 1. Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH, Crews CM.. (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology., 9 (15): [PMID:10465562] [10.1016/s0960-894x(99)00376-5] |
| 2. Kim KB, Myung J, Sin N, Crews CM.. (1999) Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency., 9 (23): [PMID:10612595] [10.1016/s0960-894x(99)00612-5] |
| 3. Rydzewski RM, Burrill L, Mendonca R, Palmer JT, Rice M, Tahilramani R, Bass KE, Leung L, Gjerstad E, Janc JW, Pan L.. (2006) Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors., 49 (10): [PMID:16686537] [10.1021/jm058289o] |
| 4. Marastoni M, Baldisserotto A, Trapella C, Gavioli R, Tomatis R.. (2006) P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors., 16 (12): [PMID:16603348] [10.1016/j.bmcl.2006.03.070] |
| 5. Baldisserotto A, Marastoni M, Fiorini S, Pretto L, Ferretti V, Gavioli R, Tomatis R.. (2008) Vinyl ester-based cyclic peptide proteasome inhibitors., 18 (6): [PMID:18294845] [10.1016/j.bmcl.2008.02.016] |
| 6. Baldisserotto A, Marastoni M, Lazzari I, Trapella C, Gavioli R, Tomatis R.. (2008) C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors., 43 (7): [PMID:17996987] [10.1016/j.ejmech.2007.10.002] |
| 7. Baldisserotto A, Marastoni M, Gavioli R, Tomatis R.. (2009) New cyclic peptide proteasome inhibitors., 19 (7): [PMID:19250821] [10.1016/j.bmcl.2009.02.046] |
| 8. Baldisserotto A, Destro F, Vertuani G, Marastoni M, Gavioli R, Tomatis R.. (2009) N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors., 17 (15): [PMID:19577931] [10.1016/j.bmc.2009.06.025] |
| 9. Baldisserotto A, Ferretti V, Destro F, Franceschini C, Marastoni M, Gavioli R, Tomatis R.. (2010) Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors., 53 (17): [PMID:20687609] [10.1021/jm100122e] |
| 10. Mahmoudi N, Garcia-Domenech R, Galvez J, Farhati K, Franetich JF, Sauerwein R, Hannoun L, Derouin F, Danis M, Mazier D.. (2008) New active drugs against liver stages of Plasmodium predicted by molecular topology., 52 (4): [PMID:18212104] [10.1128/aac.01043-07] |
| 11. Czesny B, Goshu S, Cook JL, Williamson KC.. (2009) The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity., 53 (10): [PMID:19651911] [10.1128/aac.00088-09] |
| 12. Beck J, Guminski Y, Long C, Marcourt L, Derguini F, Plisson F, Grondin A, Vandenberghe I, Vispé S, Brel V, Aussagues Y, Ausseil F, Arimondo PB, Massiot G, Sautel F, Cantagrel F.. (2012) Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors., 20 (2): [PMID:22206869] [10.1016/j.bmc.2011.11.066] |
| 13. Lansdell TA, Hewlett NM, Skoumbourdis AP, Fodor MD, Seiple IB, Su S, Baran PS, Feldman KS, Tepe JJ.. (2012) Palau'amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome., 75 (5): [PMID:22591513] [10.1021/np300231f] |
| 14. Rodrigues T, Prudêncio M, Moreira R, Mota MM, Lopes F.. (2012) Targeting the liver stage of malaria parasites: a yet unmet goal., 55 (3): [PMID:22122518] [10.1021/jm201095h] |
| 15. Vicky Avery (a), Jonathan Baell (b), Sanjay Batra (c), Jeremy Burrows (d), Soumya Bhattacharyya (c), Felix Calderon (e), Sue Charman(b), James R. Cronshaw (g), Sergio Wittlin (f), Matin Dean (g), Sandra Duffy (a), Sabine Fletcher (a), Javier Gamo (e), Zoe Hungerford (g), James Pham (h), Stuart Ralph (h), Murray N. Robertson (g), Matthew Tarnowski (g), Matthew H. Todd (g), Alice E. Williamson (g), Paul Willis (d), Karen White (b), Laura White (g), Paul M.Ylioja (g).
(a) Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, QLD 4111, Australia;
(b) Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia;
(c) Medicinal Chemistry Division, Central Drug Research Institute, PO Box 173, Lucknow, 226 001, India;
(d) Medicines for Malaria Venture, PO Box 1826, 20 rte de Pré-Bois, 1215 Geneva 15, Switzerland;
(e) Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain;
(f) Swiss Tropical and Public Health Institute, Socinstr. 57, 4051 Basel, Switzerland;
(g) School of Chemistry, The University of Sydney, NSW 2006, Australia;
(h) Department of Biochemistry & Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Victoria, 3010, Australia.. Open Source Malaria Deposition 1. http://malaria.ourexperiment.org, [10.6019/CHEMBL2113921] |
| 16. Dechy-Cabaret O, Benoit-Vical F.. (2012) Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate., 55 (23): [PMID:23075290] [10.1021/jm3005898] |
| 17. Brouwer AJ, Jonker A, Werkhoven P, Kuo E, Li N, Gallastegui N, Kemmink J, Florea BI, Groll M, Overkleeft HS, Liskamp RM.. (2012) Peptido sulfonyl fluorides as new powerful proteasome inhibitors., 55 (24): [PMID:23170994] [10.1021/jm301443r] |
| 18. Desvergne A, Genin E, Maréchal X, Gallastegui N, Dufau L, Richy N, Groll M, Vidal J, Reboud-Ravaux M.. (2013) Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome., 56 (8): [PMID:23540790] [10.1021/jm4002007] |
| 19. Sykes ML, Avery VM.. (2013) Approaches to protozoan drug discovery: phenotypic screening., 56 (20): [PMID:23927763] [10.1021/jm4004279] |
| 20. Unpublished dataset, |
| 21. Kasam V, Lee NR, Kim KB, Zhan CG.. (2014) Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening., 24 (15): [PMID:24913713] [10.1016/j.bmcl.2014.05.025] |
| 22. Terzić N, Konstantinović J, Tot M, Burojević J, Djurković-Djaković O, Srbljanović J, Štajner T, Verbić T, Zlatović M, Machado M, Albuquerque IS, Prudêncio M, Sciotti RJ, Pecic S, D'Alessandro S, Taramelli D, Šolaja BA.. (2016) Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?, 59 (1): [PMID:26640981] [10.1021/acs.jmedchem.5b01374] |
| 23. Vallone A, D'Alessandro S, Brogi S, Brindisi M, Chemi G, Alfano G, Lamponi S, Lee SG, Jez JM, Koolen KJM, Dechering KJ, Saponara S, Fusi F, Gorelli B, Taramelli D, Parapini S, Caldelari R, Campiani G, Gemma S, Butini S.. (2018) Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues., 150 [PMID:29571157] [10.1016/j.ejmech.2018.03.024] |
| 24. Diedrich D, Stenzel K, Hesping E, Antonova-Koch Y, Gebru T, Duffy S, Fisher G, Schöler A, Meister S, Kurz T, Avery VM, Winzeler EA, Held J, Andrews KT, Hansen FK.. (2018) One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites., 158 [PMID:30245402] [10.1016/j.ejmech.2018.09.018] |
| 25. Lee MJ, Bhattarai D, Yoo J, Miller Z, Park JE, Lee S, Lee W, Driscoll JJ, Kim KB.. (2019) Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib., 62 (9): [PMID:30964987] [10.1021/acs.jmedchem.8b01943] |
| 26. Gilda Padalino, Avril Coghlan, Giampaolo Pagliuca, Josephine F. Thomas, Matthew Berriman, Karl F. Hoffmann. (2023) Using ChEMBL to complement schistosome drug discovery, [10.6019/CHEMBL5096127] |
| 27. Zhang Z, Liu X, Zhao L, Zhou Y, Shi J, Chen W, Li J.. (2022) A review on the treatment of multiple myeloma with small molecular agents in the past five years., 229 [PMID:34974338] [10.1016/j.ejmech.2021.114053] |
